Leap Therapeutics (LPTX): Price-to-Projected Revenue Ratio

LPTX (Leap Tx) - company brandmark

High costs in the final stages of antibody testing are creating financial pressure on Leap Therapeutics, Inc. (LPTX). The forward P/S history indicates a support level where 96.40 reflects the metric's baseline. Patent protection of developments will ensure a stable margin, while current revenue is based on grants and licenses from partners in the gastrointestinal therapy sector.

LPTX Leap Tx: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 04/01/2023

Analytical breakdowns for Leap Therapeutics (LPTX)

- stock exchange capitalization data:
Summary company analysis:Leap Tx LPTX
Manufactured products of leaptx.com

Forward P/S compares current market capitalization with projected revenue, reflecting investors' willingness to pay a premium for future income streams. For Leap Therapeutics, Inc. (LPTX), this indicator measures market optimism regarding the commercialization of targeted immunotherapy and the success of Phase II clinical trials, allowing for an assessment of the asset's fair value through the company's P/S expectations.

Competitor analysis

ImmunityBio Inc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Corp IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (arcusbio.com) - Market Cap to Projected Revenue|Zymeworks Biopharmaceuticals (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Tango Pharma (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune)|Forward Price to Sales LYEL|innate-pharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pyxis Oncology|Compugen Limited (CGEN) - Price-to-Projected Revenue Ratio|IO Biotech, Inc. - Forward Price to Sales|STRO (sutrobio.com) - Forward P/S Multiple|Forward P/S Multiple MiNK Therapeutics Inc.|Price-to-Projected Revenue Ratio werewolftx.com (HOWL)|IMMX: Future Price to Revenue|alxoncology.com - Forward Price-to-Revenue Multiple|CUE - Forward Price-to-Revenue Multiple|PDSB - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Sonnet BioTherapeutics Holdings SONN|MAIA: Forward P/S Multiple|LIMN - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple LVTX|Market Cap to Projected Revenue NXTC (NextCure)|Forward P/S Multiple INTS|Market Cap to Expected Sales Ratio Sensei Biotherapeutics, Inc.|Forward P/S Multiple TOVX (Theriva Corp)|Market Cap to Expected Sales Ratio gritstonebio.com (GRTS)|kinetabio.com - Forward P/S Multiple|NexImmune (NEXI) - Forward Price-to-Revenue Multiple|turnstonebio.com (TSBX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vaccinex, Inc (VCNX)|Forward Price-to-Revenue Multiple HARP